

BEST AVAILABLE COPY

DOCKET NO.: ISPH-0593

PATENT

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently Amended): An antisense ~~compound~~ oligonucleotide 12 to 30 nucleobases in length targeted and 100% complementary to a nucleic acid molecule encoding human apolipoprotein (a) (SEQ ID NO: 3), wherein said ~~compound~~ oligonucleotide specifically hybridizes with said nucleic acid molecule encoding human apolipoprotein (a) and inhibits the expression of human apolipoprotein (a), and wherein said oligonucleotide comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar moiety, and a modified nucleobase.

Claims 2-4 (Canceled)

Claim 5 (Currently Amended): The ~~compound~~ oligonucleotide of claim ~~4~~ 1 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (Canceled)

Claim 7 (Currently Amended): The ~~compound~~ oligonucleotide of claim ~~6~~ 1 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

DOCKET NO.: ISPH-0595

PATENT

Claim 8 (Canceled)

Claim 9 (Currently Amended): The ~~compound~~ oligonucleotide of claim ~~8~~ 1 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (Currently Amended): The ~~compound~~ oligonucleotide of claim ~~2~~ 1 ~~which wherein the antisense oligonucleotide is~~ a chimeric oligonucleotide.

Claim 11 (Currently Amended): An antisense compound 12 to 30 nucleobases in length targeted and 100% complementary to ~~which specifically hybridizes with~~ at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding human apolipoprotein (a) (SEQ ID NO: 3),

wherein said compound specifically hybridizes with said active site, and

wherein said oligonucleotide comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar moiety, and a modified nucleobase.

Claim 12 (Currently Amended): A composition comprising the ~~compound~~ oligonucleotide of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (Original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (Canceled)

DOCKET NO.: ISPH-0595

PATENT

Claim 15 (Previously Presented): A method of inhibiting the expression of human apolipoprotein (a) in cells or tissues comprising contacting cells or tissues in vitro with the compound of claim 1 so that expression of human apolipoprotein (a) is inhibited.

Claims 16-20 (Canceled).